Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

彭布罗利珠单抗 医学 肿瘤科 内科学 肿瘤微环境 尿路上皮癌 生物标志物 临床试验 免疫疗法 尿路上皮癌 精密医学 病理 癌症 生物信息学 梅德林 实体瘤
作者
Joaquim Bellmunt,Ronald de Wit,Yves Fradet,Miguel A. Climent,Daniel P. Petrylak,Jae-Lyun Lee,Lawrence Fong,Andrea Necchi,Cora N. Sternberg,Peter H. O'Donnell,Thomas Powles,Elizabeth R. Plimack,Dean F. Bajorin,Arjun V. Balar,Daniel Castellano,Toni K. Choueiri,Stephane Culine,Winald Gerritsen,Howard Gurney,David I. Quinn
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (10): 2050-2060 被引量:48
标识
DOI:10.1158/1078-0432.ccr-21-3089
摘要

PURPOSE: In an exploratory analysis, we investigated the association between programmed death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell-inflamed gene expression profile (TcellinfGEP), and stromal signature with outcomes of pembrolizumab in urothelial carcinoma (UC). PATIENTS AND METHODS: Patients with advanced UC received first-line pembrolizumab 200 mg every 3 weeks in the single-arm phase II KEYNOTE-052 trial (NCT02335424) and salvage pembrolizumab 200 mg every 3 weeks or chemotherapy (paclitaxel/docetaxel/vinflunine) in the randomized phase III KEYNOTE-045 trial (NCT02256436). The association of each biomarker (continuous variable) with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was evaluated using logistic regression (ORR) and Cox PH (PFS, OS), adjusted for ECOG PS; nominal P values were calculated without multiplicity adjustment (one-sided, pembrolizumab; two-sided, chemotherapy). Significance was prespecified at α = 0.05. RESULTS: In KEYNOTE-052, PD-L1, TMB, and TcellinfGEP were significantly associated with improved outcomes; stromal signature was significantly associated with worse outcomes. In KEYNOTE-045, although findings for TMB and TcellinfGEP with pembrolizumab were consistent with those of KEYNOTE-052, PD-L1 was not significantly associated with improved outcomes, nor was stromal signature associated with worse outcomes with pembrolizumab; chemotherapy was not associated with outcomes in a consistent manner for any of the biomarkers. Hazard ratio (HR) estimates at prespecified cutoffs showed an advantage for pembrolizumab versus chemotherapy regardless of PD-L1 or TMB, with a trend toward lower HRs in the combined positive score ≥10 and the TMB ≥175 mutation/exome subgroup. For TcellinfGEP, PFS and OS HRs were lower in the TcellinfGEP-nonlow subgroup regardless of treatment. CONCLUSIONS: Multiple biomarkers characterizing the tumor microenvironment may help predict response to pembrolizumab monotherapy in UC, and potential clinical utility of these biomarkers may be context-dependent.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
唐鸭鸭完成签到 ,获得积分10
1秒前
zzt完成签到,获得积分10
1秒前
小巧的中蓝完成签到 ,获得积分10
1秒前
CAOHOU的应助被明亮的新筠采纳,获得10
1秒前
机灵的沂完成签到,获得积分10
2秒前
2秒前
今后的应助被木子萌采纳,获得10
2秒前
yyyy发布了新的文献求助10
2秒前
woninone完成签到 ,获得积分10
3秒前
乔治发布了新的文献求助10
3秒前
3秒前
优秀的方盒完成签到 ,获得积分10
4秒前
Well发布了新的文献求助10
5秒前
Eric的应助被wjt采纳,获得10
5秒前
5秒前
Ail完成签到,获得积分10
6秒前
aaaQIU发布了新的文献求助10
6秒前
9秒前
yu完成签到,获得积分10
10秒前
10秒前
天天快乐的应助被科研通管家采纳,获得10
10秒前
小马甲的应助被科研通管家采纳,获得10
10秒前
11秒前
初一发布了新的文献求助10
11秒前
QDU的应助被今天没有哭鸭采纳,获得10
11秒前
Lucas的应助被科研通管家采纳,获得10
11秒前
传奇3的应助被科研通管家采纳,获得10
11秒前
充电宝的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
希望天下0贩的0的应助被Well采纳,获得10
11秒前
赘婿的应助被科研通管家采纳,获得10
11秒前
11秒前
Hello的应助被科研通管家采纳,获得10
11秒前
刀河王发布了新的文献求助10
12秒前
04d的应助被科研通管家采纳,获得10
12秒前
852的应助被科研通管家采纳,获得10
12秒前
巴扎嘿完成签到,获得积分10
12秒前
12秒前
小马甲的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191571
求助须知:如何正确求助?哪些是违规求助? 9578332
关于积分的说明 21858634
捐赠科研通 7790907
什么是DOI,文献DOI怎么找? 3436656
关于科研通互助平台的介绍 2560375
邀请新用户注册赠送积分活动 2483446